Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13194359 | 0.84 | EPHX1 (0.39) | EPHX1CA1CA2CA12CA7 | |
| SCHEMBL10133161 | 0.81 | CA1 (0.58) | EPHX1CA1CA2CA12CA7 | |
| SCHEMBL1051785 | 0.79 | EPHX1 (0.39) | EPHX1CA1CA2CA12CA7 | |
| SCHEMBL22955433 | 0.79 | EPHX1 (0.39) | EPHX1CA1CA2CA12CA7 | |
| SCHEMBL10115090 | 0.79 | EPHX1 (0.64) | EPHX1CA1CA2CA12CA7 | |
| SCHEMBL9111448 | 0.79 | EPHX1 (0.39) | EPHX1CA1CA2CA12CA7 | |
| SCHEMBL15609677 | 0.79 | EPHX1 (0.39) | EPHX1CA1CA2CA12CA7 | |
| SCHEMBL13972896 | 0.77 | EPHX1 (0.68) | EPHX1CA1CA2CA12CA7 | |
| SCHEMBL15904262 | 0.76 | EPHX1 (0.61) | EPHX1CA1CA2CA12CA7 | |
| SCHEMBL23862451 | 0.76 | EPHX1 (0.46) | EPHX1GRIA1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464623-B1 | THE RING OPENING OF LACTONES AND LACTAMS | NOVARTIS AG (CH) | 2020-11-04 | — | — | EP | disclosed |
| US-8779198-B2 | Ring opening of lactones and lactams | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20120165555-A1 | RING OPENING OF LACTONES AND LACTAMS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-8084485-B2 | 6-(aminoalkyl)indazoles | VITAE PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-7919529-B2 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides | NOVARTIS AG (CH) | 2011-04-05 | — | — | US | disclosed |
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | disclosed |
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| EP-2266951-A1 | Organic compounds | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-7851642-B2 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compound | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| US-20100298328-A1 | 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes | VITAE PHARMACEUTICALS, INC | 2010-11-25 | — | — | US | disclosed |
| WO-2006061426-A1 | ω-PHENYLOCTANAMIDES | SPEEDEL EXPERIMENTA AG (CH) | 2006-06-15 | — | — | WO | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005051895-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0678503-A1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | REN, AGTR1, AGTR2 | EPHX1 692/4885CA1 4586/4885CA2 598/4885 |
| US-20100298328-A1 | 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes | REN, AGTR1, AGTR2 | EPHX1 125/4885CA1 4781/4885CA2 2137/4885 |
| US-20120165555-A1 | RING OPENING OF LACTONES AND LACTAMS | LSS, APH1A, OTUB1 | EPHX1 1368/4885CA1 1473/4885CA2 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.